A comprehensive analysis of nearly 1,600 tumor samples has found that CT-X genes are expressed in nearly half the breast cancers that lack the estrogen receptor (ER). CT-X gene products are the targets of therapeutic cancer vaccines already in phase III clinical trials for lung cancer and melanoma. The study - to be published in the Early Edition of the Proceedings of the National Academy of Sciences this week - was led by the international Ludwig Institute for Cancer Research (LICR).
More...